JP2022537384A5 - - Google Patents
Info
- Publication number
- JP2022537384A5 JP2022537384A5 JP2021575509A JP2021575509A JP2022537384A5 JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5 JP 2021575509 A JP2021575509 A JP 2021575509A JP 2021575509 A JP2021575509 A JP 2021575509A JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- azacitidine
- days
- pharmaceutical composition
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864413P | 2019-06-20 | 2019-06-20 | |
| US62/864,413 | 2019-06-20 | ||
| PCT/US2020/038760 WO2020257665A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537384A JP2022537384A (ja) | 2022-08-25 |
| JP2022537384A5 true JP2022537384A5 (cg-RX-API-DMAC10.html) | 2023-06-08 |
Family
ID=71528047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| JP2021575509A Pending JP2022537384A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Country Status (11)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| US12214054B2 (en) | 2015-11-30 | 2025-02-04 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Cpf1に基づくゲノム編集の治療適用 |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| TWI887234B (zh) | 2019-04-14 | 2025-06-21 | 美國公爵大學 | 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除 |
| WO2022187288A2 (en) * | 2021-03-01 | 2022-09-09 | Duke University | Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness |
| JP7898763B2 (ja) * | 2021-04-05 | 2026-08-03 | ピノットバイオ インコーポレイテッド | 4’-チオ-5-アザ-2’-デオキシシチジンおよびベネトクラクスの併用療法 |
| WO2022240788A1 (en) * | 2021-05-11 | 2022-11-17 | Abbvie Inc. | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine |
| BR112023023677A2 (pt) * | 2021-05-11 | 2024-02-20 | Abbvie Inc | Regimes de dosagem de venetoclax para o uso no tratamento de síndromes mielodisplásicas em combinação com azacitidina |
| US20250312327A1 (en) * | 2021-10-14 | 2025-10-09 | Pharos Ibio Co., Ltd | Composition for combination therapy, comprising 2,3,5-substituted thiophene compound |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3782612T3 (da) | 2008-05-15 | 2024-01-15 | Celgene Corp | Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf |
| WO2015168466A1 (en) | 2014-05-01 | 2015-11-05 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| ES2935114T3 (es) | 2014-09-05 | 2023-03-01 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| EA201790543A1 (ru) | 2014-09-08 | 2017-07-31 | Селджин Корпорейшн | Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1 |
| CA3002029A1 (en) | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| MD3362066T2 (ro) | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Terapie combinată pentru tratamentul tumorilor maligne |
| MX373363B (es) | 2015-11-05 | 2020-05-21 | Celgene Quanticel Res Inc | Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina. |
| SG10201913290QA (en) * | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| WO2018106984A1 (en) * | 2016-12-09 | 2018-06-14 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| EP4201399A3 (en) | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| IL271946B (en) * | 2017-07-09 | 2022-09-01 | Biosight Ltd | Combination cancer therapy |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Cd70組合治療 |
-
2020
- 2020-06-19 WO PCT/US2020/038772 patent/WO2020257671A1/en not_active Ceased
- 2020-06-19 MX MX2021015993A patent/MX2021015993A/es unknown
- 2020-06-19 JP JP2021575387A patent/JP2022537551A/ja active Pending
- 2020-06-19 CA CA3143711A patent/CA3143711A1/en active Pending
- 2020-06-19 US US17/620,545 patent/US12447171B2/en active Active
- 2020-06-19 CN CN202080057984.0A patent/CN115066243A/zh active Pending
- 2020-06-19 JP JP2021575509A patent/JP2022537384A/ja active Pending
- 2020-06-19 CA CA3143719A patent/CA3143719A1/en active Pending
- 2020-06-19 MX MX2021015992A patent/MX2021015992A/es unknown
- 2020-06-19 AU AU2020297596A patent/AU2020297596A1/en not_active Abandoned
- 2020-06-19 BR BR112021025537A patent/BR112021025537A2/pt not_active IP Right Cessation
- 2020-06-19 WO PCT/US2020/038760 patent/WO2020257665A1/en not_active Ceased
- 2020-06-19 EP EP20737783.9A patent/EP3986404A1/en not_active Withdrawn
- 2020-06-19 KR KR1020227001609A patent/KR20220050874A/ko not_active Ceased
- 2020-06-19 BR BR112021025375A patent/BR112021025375A2/pt active Search and Examination
- 2020-06-19 KR KR1020227001605A patent/KR20220024639A/ko not_active Ceased
- 2020-06-19 CN CN202080058723.0A patent/CN114727996A/zh active Pending
- 2020-06-19 EP EP20737778.9A patent/EP3986403A1/en active Pending
- 2020-06-19 US US17/620,541 patent/US20220249528A1/en active Pending
- 2020-06-19 AU AU2020296179A patent/AU2020296179A1/en not_active Abandoned
-
2021
- 2021-12-19 IL IL289115A patent/IL289115A/en unknown
- 2021-12-19 IL IL289110A patent/IL289110A/en unknown